DOCSLIB.ORG

The Structure of Salvarsan

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The Structure of Salvarsan http://researchcommons.waikato.ac.nz/ Research Commons at the University of Waikato Copyright Statement: The digital copy of this thesis is protected by the Copyright Act 1994 (New Zealand). The thesis may be consulted by you, provided you comply with the provisions of the Act and the following conditions of use: Any use you make of these documents or images must be for research or private study purposes only, and you may not make them available to any other person. Authors control the copyright of their thesis. You will recognise the author’s right to be identified as the author of the thesis, and due acknowledgement will be made to the author where appropriate. You will obtain the author’s permission before publishing any material from the thesis. A Reinvestigation of Salvarsan and Related Arsenic Chemistry. A thesis submitted in fulfilment of the requirements for the degree of Doctor of Philosophy in Chemistry at The University of Waikato by Nicholas Lloyd 2011 i “Life is a chemical incident, A normal oxidation, A fluorescence of the brain” Paul Ehrlich 1872 ii Abstract In 1910 the first deliberately targeted search for a new chemotherapeutic agent came to fruition when Paul Ehrlich introduced Salvarsan for the treatment of syphilis. This thesis presents a detailed review of the history and literature leading up to and following on from Ehrlich‟s discovery and thoroughly investigates the chemistry of Salvarsan and related species. A series of arylarsonic acids was prepared and fully characterised by electrospray mass spectrometry, NMR and X-ray crystallography for six examples. A detailed analysis of the hydrogen bonding in crystals of these molecules showed that they adopt several characteristic motifs which govern the packing in the crystals. Two of the examples containing NH2 groups crystallised as zwitterions while one NH2 containing example containing other bulky groups was is its molecular form. Salvarsan (cyclo 3-amino-4-hydroxyphenylarsenic(I)) was prepared by several different methods and analysed in detail using high resolution electrospray mass spectroscopy. This showed that Salvarsan consists of small cyclic species of the type (RAs)n where R is 3-NH2-4-OHC6H3 and n is three or greater. The dominant species in an aqueous solution of Salvarsan were found to be (RAs)3 and (RAs)5 . A detailed analysis is presented of impurities in Salvarsan prepared by different methods and also in a sample of original commercial Salvarsan. Mixtures of (RAs)n and (R‟As)n exchange R groups in aqueous solution at room temperature, as shown by ESI-MS. ESI-MS studies are reported for the oxidation product of Salvarsan, RAs(OH)2 (commercially known as Mapharsen) and related As(III) compounds. Oligomers iii involving As-O-As linkages were found in solution and one tetrameric example (R = 3- NO2-4-OHC6H3) was isolated and structurally characterised. Preliminary ESI-MS studies showed that As(III) species bind to thioredoxin, a possible target for the pharmaceutical activity of Salvarsan and its derivatives. iv Acknowledgments Thanks to everyone who has supported me throughout this project, especially Professor Brian Nicholson for pushing me through to completion and supplying me with seedling leeks for my garden. Big thanks also to Wendy Jackson and Pat Gread for technical assistance, support and friendly conversation throughout this project. Thanks to The Marsden Fund administered by the Royal Society of New Zealand for financial support. Thanks to Professor Steve Reithmiller for visiting to assist with the project, information on Paul Ehrlich and sourcing original samples of Salvarsan. Thanks to Pfizer for their generous donation of Mapharsen from the Parke Davis Archives Many thanks to Professor Hugh Morgan and Dr. Ron Ronimus for assistance and many helpful suggestions in understanding the biological aspects of this project. Thanks to all the other students who i have shared a lab with over the years, especially Carol, Bevan, Steve, Narendra, Kelly and Megan for assistance with Microsoft word. Thanks to everyone else who has offered advice, support, encouragement and conversation over the years I have been at Waikato. Finally thanks to Mum and Dad for constant support and encouragement. v Table of Contents Abstract ......................................................................................................................... iii Acknowledgments ......................................................................................................... v Table of Contents ......................................................................................................... vi List of Figures .............................................................................................................. xii List of Tables ............................................................................................................... xv 1 Chapter One - Introduction .................................................................................. 17 1.1 Some background on arsenic ........................................................................ 17 1.1.1 Pre-alchemy ........................................................................................... 17 1.1.2 Discovery of elemental arsenic.............................................................. 18 1.1.3 Geber or Pseudo-Geber? ........................................................................ 20 1.1.4 Chinese alchemy .................................................................................... 20 1.1.5 Problems ................................................................................................ 21 1.1.6 Albertus Magnus ................................................................................... 21 1.2 Syphilis ......................................................................................................... 22 1.2.1 Early medicine ....................................................................................... 22 1.2.2 A new disease ........................................................................................ 23 1.2.3 Origins ................................................................................................... 25 1.2.4 A complicated disease ........................................................................... 27 1.2.5 New disease needs new cure ................................................................. 30 1.2.6 Competing cures .................................................................................... 31 1.2.7 Arsenic ................................................................................................... 33 1.3 More on syphilis ........................................................................................... 34 1.3.1 More confusion. ..................................................................................... 35 vi 1.3.1.1 Many diseases – one name ............................................................. 36 1.3.1.2 Different stages .............................................................................. 36 1.3.1.3 Syphilis – the great imitator ........................................................... 38 1.3.2 Other interesting points on syphilis ....................................................... 39 1.3.3 Advances in treatment ........................................................................... 40 1.4 Paul Ehrlich ................................................................................................... 42 1.4.1 Beginnings ............................................................................................. 42 1.4.2 Chemistry in Ehrlich‟s time ................................................................... 44 1.4.3 Paul Ehrlich and Robert Koch ............................................................... 44 1.4.4 The Japanese link................................................................................... 46 1.4.5 Trypanosomes and arsenic..................................................................... 49 1.4.6 Atoxyl .................................................................................................... 50 1.4.7 Ehrlich and atoxyl .................................................................................. 53 1.4.8 Enter Alfred Bertheim ........................................................................... 54 1.4.9 Ehrlich‟s numbering system .................................................................. 58 1.5 Salvarsan ....................................................................................................... 59 1.5.1 Discovery of Salvarsan .......................................................................... 59 1.5.2 The Salvarsan wars ................................................................................ 64 1.5.3 Administration of Salvarsan .................................................................. 67 1.5.4 After Salvarsan ...................................................................................... 71 1.5.5 Commercial preparation of Salvarsan ................................................... 73 1.5.6 The end of Ehrlich ................................................................................. 74 1.6 Literature ....................................................................................................... 77 1.6.1 The Salvarsan investigations ................................................................. 79 1.6.2 Neosalvarsan .........................................................................................
Load more

Recommended publications
  • Pre-Antibiotic Therapy of Syphilis Charles T
    University of Kentucky UKnowledge Microbiology, Immunology, and Molecular Microbiology, Immunology, and Molecular Genetics Faculty Publications Genetics 2016 Pre-Antibiotic Therapy of Syphilis Charles T. Ambrose University of Kentucky, [email protected] Right click to open a feedback form in a new tab to let us know how this document benefits oy u. Follow this and additional works at: https://uknowledge.uky.edu/microbio_facpub Part of the Medical Immunology Commons Repository Citation Ambrose, Charles T., "Pre-Antibiotic Therapy of Syphilis" (2016). Microbiology, Immunology, and Molecular Genetics Faculty Publications. 83. https://uknowledge.uky.edu/microbio_facpub/83 This Article is brought to you for free and open access by the Microbiology, Immunology, and Molecular Genetics at UKnowledge. It has been accepted for inclusion in Microbiology, Immunology, and Molecular Genetics Faculty Publications by an authorized administrator of UKnowledge. For more information, please contact [email protected]. Pre-Antibiotic Therapy of Syphilis Notes/Citation Information Published in NESSA Journal of Infectious Diseases and Immunology, v. 1, issue 1, p. 1-20. © 2016 C.T. Ambrose This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. This article is available at UKnowledge: https://uknowledge.uky.edu/microbio_facpub/83 Journal of Infectious Diseases and Immunology Volume 1| Issue 1 Review Article Open Access PRE-ANTIBIOTICTHERAPY OF SYPHILIS C.T. Ambrose, M.D1* 1Department of Microbiology, College of Medicine, University of Kentucky *Corresponding author: C.T. Ambrose, M.D, College of Medicine, University of Kentucky Department of Microbiology, E-mail: [email protected] Citation: C.T.
    [Show full text]
  • Arsinothricin, an Arsenic-Containing Non-Proteinogenic Amino Acid Analog of Glutamate, Is a Broad-Spectrum Antibiotic
    ARTICLE https://doi.org/10.1038/s42003-019-0365-y OPEN Arsinothricin, an arsenic-containing non-proteinogenic amino acid analog of glutamate, is a broad-spectrum antibiotic Venkadesh Sarkarai Nadar1,7, Jian Chen1,7, Dharmendra S. Dheeman 1,6,7, Adriana Emilce Galván1,2, 1234567890():,; Kunie Yoshinaga-Sakurai1, Palani Kandavelu3, Banumathi Sankaran4, Masato Kuramata5, Satoru Ishikawa5, Barry P. Rosen1 & Masafumi Yoshinaga1 The emergence and spread of antimicrobial resistance highlights the urgent need for new antibiotics. Organoarsenicals have been used as antimicrobials since Paul Ehrlich’s salvarsan. Recently a soil bacterium was shown to produce the organoarsenical arsinothricin. We demonstrate that arsinothricin, a non-proteinogenic analog of glutamate that inhibits gluta- mine synthetase, is an effective broad-spectrum antibiotic against both Gram-positive and Gram-negative bacteria, suggesting that bacteria have evolved the ability to utilize the per- vasive environmental toxic metalloid arsenic to produce a potent antimicrobial. With every new antibiotic, resistance inevitably arises. The arsN1 gene, widely distributed in bacterial arsenic resistance (ars) operons, selectively confers resistance to arsinothricin by acetylation of the α-amino group. Crystal structures of ArsN1 N-acetyltransferase, with or without arsinothricin, shed light on the mechanism of its substrate selectivity. These findings have the potential for development of a new class of organoarsenical antimicrobials and ArsN1 inhibitors. 1 Department of Cellular Biology and Pharmacology, Florida International University, Herbert Wertheim College of Medicine, Miami, FL 33199, USA. 2 Planta Piloto de Procesos Industriales Microbiológicos (PROIMI-CONICET), Tucumán T4001MVB, Argentina. 3 SER-CAT and Department of Biochemistry and Molecular Biology, University of Georgia, Athens, GA 30602, USA.
    [Show full text]
  • Chemsherpa 管理対象物質 Ver2.02.00 説明書
    chemSHERPA 管理対象物質 Ver2.02.00 説明書 chemSHERPA 事務局 内容 1. はじめに ....................................................................................................................................... 2 2. 管理対象物質リストに関わる用語の定義 ....................................................................................... 3 3. 管理対象物質 Ver2.02.00 について............................................................................................ 4 3.1 管理対象基準 ..................................................................................................................... 4 3.1.1 LR01: 日本 化審法 第一種特定化学物質 ................................................................. 5 3.1.2 LR02︓米国 有害物質規制法（Toxic Substances Control Act︓TSCA）使用禁止 または制限の対象物質（第 6 条） .............................................................................................. 5 3.1.3 LR03︓EU ELV 指令 2000/53/EC ........................................................................... 6 3.1.4 LR04︓EU RoHS 指令 2011/65/EU ANNEX II ..................................................... 6 3.1.5 LR05︓EU POPs 規則 (EU) 2019/1021 ANNEX I ............................................... 7 3.1.6 LR06︓EU REACH 規則 (EC) No 1907/2006 Candidate List of SVHC for Authorisation（認可対象候補物質）および ANNEX XIV（認可対象物質） ........................... 7 3.1.7 LR07︓EU REACH 規則 (EC) No 1907/2006 ANNEX XVII（制限対象物質） . 10 3.1.8 LR08: 欧州 医療機器規則 Annex I 10.4 化学物質 ............................................. 10 3.1.9 IC01︓Global Automotive Declarable Substance List (GADSL) ....................... 11 3.1.10 IC02 ︓ IEC 62474 DB Declarable
    [Show full text]
  • Multi-Residue Determination of Organic Arsenical Drugs in Feeds by LC-MS/MS
    Multi-Residue Determination of Organic Arsenical Drugs in Feeds by LC-MS/MS Geneviève Grenier, Melanie Titley & Lise-Anne Prescott AAFCO Laboratory Methods and Services Committee meeting 2016-01-18 Background • Animal Feed Division of CFIA identified a high priority need for the determination of three organic arsenicals (arsanilic acid, roxarsone and nitarsone) at residue levels in animal feed • These are withdrawal drugs and are priority food contaminants • Current test methods are at guarantee levels greater than 10% minimum use rate • Therefore, current methods not well suited for residue or traceback testing • Requested feed residue LOQ of 1 mg/kg for all three organic arsenicals 2 Background • UHPLC-PDA Challenges • Extract were very dirty • Tried sample clean-up using Oasis MAX SPE • Still very dirty • HPLC Challenges • Compounds elute too easily • Analytical column must : retain and separate compounds, and give good peak shape • Analytical column : Phenomenex Onyx Monolithic C18 100 X 3.0mm 3 Background • LC/MS/MS method (positive mode) • Column: Phenomenex Onyx Monolithic C18 100 X 3.0mm • Linearity problems with Internal Standard (IS) • Internal standard – 4-hydroxyphenylarsonic acid • Peak area of the internal standard increased with increasing analyte concentration • Cause • 4-hydroxyphenyl arsanic acid co-elute with Arsanilic acid and have similar m/z 4 New method - summary • Liquid chromatography combined with atomic and molecular mass spectrometry for speciation of arsenic in chicken liver. Peng et. al., Journal of Chromatography
    [Show full text]
  • REVIEW Modern Japanese Medical History and the European In¯Uence
    REVIEW Modern Japanese medical history and the European in¯uence Yoshio Izumi and Kazuo Isozumi1 Department of Neurology, Tokai University School of Medicine, Kanagawa 1 Department of Neurology, Ashikaga Red Cross Hospital, Tochigi, Japan (Received for publication on January 19, 2001) Abstract. Before the ®rst European visited Japan in 1549, traditional Chinese medicine was mainly employed in Japan. Francisco de Xavier, a missionary of the Society of Jesus, tried to promote the introduction of Christianity by providing a medical service for Japanese citizens. However, Japan implemented a national isolation policy in 1639 and cut off diplomatic relations with the rest of the world, except Holland and China. For over 200 years, until the American admiral Matthew Perry forced Japan to open its doors in 1853, Japan learned about western medicine only from doctors of the Dutch merchants' of®ce or from Dutch medical books. After 1853, Western medicine was rapidly introduced into Japan, and great achievements by Japanese medical doctors soon followed, such as the serum therapy for tetanus, the discovery of the plague and dysentery bacilli, the invention of Salvarsan for the treatment of syphilis, and the demonstration of the neurosyphilis spirochete. (KeioJMed50(2): 91±99, June 2001) Key words: Kaitai-Shinsho, Seishu Hanaoka, Siebold, Pompe, Shibasaburo Kitasato Xavier's Visit to Japan and Obtaining the permission of the feudal lord of Satsuma, ``Southern Barbarian Style Surgery'' Shimazu, he engaged in missionary work in the western parts of Japan. According to the record of Nippon- The God of medicine in Europe is Asclepius, but the Seikyo-Shi (History of Western Religion in Japan), person honored as the founder of medicine is Hippo- Xavier nursed sick persons during his missionary work.
    [Show full text]
  • National Center for Toxicological Research (NCTR) Science Advisory Board (SAB)
    National Center for Toxicological Research (NCTR) Science Advisory Board (SAB) November 2, 2016 Crowne Plaza 201 S. Shackleford Road Little Rock, AR 72211 TABLE OF CONTENTS FDA Center Perspectives 1 Center for Biologics Evaluation and Research Center for Drug Evaluation and Research Center for Devices and Radiological Health Center for Tobacco Products Center for Veterinary Medicine Office of Regulatory Affairs Discussion of NCTR Research (SAB Members) 120 1 P R O C E E D I N G S Agenda Item: FDA Center Perspectives DR. PHILBERT: Good morning. Our first presentation in a series from our colleagues at FDA is from Carolyn, Center for Biologics Evaluation and Research. DR. WILSON: Good morning. Thank you. I am going to start with an overview of the products we regulate just to orient some of you who may be new on the advisory board. Then I will go into the priorities for our scientific research program, as well as some examples of ongoing and potential future collaborations with NCTR. We regulate what are called complex biologic products, so things like monoclonal antibodies and most recombinant proteins are regulated in the Center for Drugs. But we regulate things like blood, blood components and derivatives, vaccines both preventative and therapeutic, the novel areas like cell and gene therapies, including stem cells, and that does include things like CRISPR modification of cells. Certain human tissues, live biotherapeutics and, yes, that includes fetal transplantation, allergenic products which actually, although that is a single line, represents over 1200 different extracts that are used both for diagnosis 2 and treatment of allergies, and then certain related devices, as well.
    [Show full text]
  • Alfa Laval Black and Grey List, Rev 14.Pdf 2021-02-17 1678 Kb
    Alfa Laval Group Black and Grey List M-0710-075E (Revision 14) Black and Grey list – Chemical substances which are subject to restrictions First edition date. 2007-10-29 Revision date 2021-02-10 1. Introduction The Alfa Laval Black and Grey List is divided into three different categories: Banned, Restricted and Substances of Concern. It provides information about restrictions on the use of Chemical substances in Alfa Laval Group’s production processes, materials and parts of our products as well as packaging. Unless stated otherwise, the restrictions on a substance in this list affect the use of the substance in pure form, mixtures and purchased articles. - Banned substances are substances which are prohibited1. - Restricted substances are prohibited in certain applications relevant to the Alfa Laval group. A restricted substance may be used if the application is unmistakably outside the scope of the legislation in question. - Substances of Concern are substances of which the use shall be monitored. This includes substances currently being evaluated for regulations applicable to the Banned or Restricted categories, or substances with legal demands for monitoring. Product owners shall be aware of the risks associated with the continued use of a Substance of Concern. 2. Legislation in the Black and Grey List Alfa Laval Group’s Black and Grey list is based on EU legislations and global agreements. The black and grey list does not correspond to national laws. For more information about chemical regulation please visit: • REACH Candidate list, Substances of Very High Concern (SVHC) • REACH Authorisation list, SVHCs subject to authorization • Protocol on persistent organic pollutants (POPs) o Aarhus protocol o Stockholm convention • Euratom • IMO adopted 2015 GUIDELINES FOR THE DEVELOPMENT OF THE INVENTORY OF HAZARDOUS MATERIALS” (MEPC 269 (68)) • The Hong Kong Convention • Conflict minerals: Dodd-Frank Act 1 Prohibited to use, or put on the market, regardless of application.
    [Show full text]
  • Qingqing Liu
    Speciation of arsenic metabolites in chicken meat and in human cells by Qingqing Liu A thesis submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy Medical Sciences – Laboratory Medicine and Pathology University of Alberta © Qingqing Liu, 2016 Abstract A phenylarsenical, 3-nitro-4-hydroxyphenylarsonic acid (Roxarsone®, Rox), has been used extensively as a poultry feed additive for over 60 years. However, little is known about the concentrations of different arsenic species present in chicken meat as a consequence of feeding Rox to chickens. The first objective of my thesis research is to study the speciation of Rox in chicken meat, providing relevant information on human exposure to arsenic through the ingestion of chicken meat. The second objective is to study accumulation, transport, and metabolism of Rox and the related arsenic species using human cells, improving a mechanistic understanding. To quantify arsenic species in chicken meat, I first developed an enzyme-assisted extraction method which enhanced the extraction efficiency of arsenic from 28% using water/methanol extraction to 55% using papain digestion. The efficiency was further enhanced to 88% by using ultrasonication combined with the papain digestion. Arsenic species were separated using high performance liquid chromatography (HPLC). Inductively coupled plasma mass spectrometry (ICPMS) and electrospray ionization tandem mass spectrometry (ESI-MS/MS) were used in combination to quantify and identify arsenic species. The method of papain-assisted extraction and HPLC-ICPMS determination achieved detection limits of 1.0-1.8 µg arsenic per kg chicken breast meat for arsenobetaine (AsB), inorganic arsenite (AsIII), dimethylarsinic acid (DMA), monomethylarsonic acid (MMA), inorganic arsenate (AsV), Rox, and N-acetyl-4-hydroxy-m-arsanilic acid (NAHAA).
    [Show full text]
  • Of Rabbits and Men: the Tale of Paul Ehrlich in Our Modern World Of
    Of Rabbits and Men: The Tale of Paul Ehrlich In our modern world of chemotherapy, antibiotics and antivirals, it might come as a surprise to find that the origin of all these treatments can be traced back to rabbits; the cute and fluffy kind. To understand why, we need to go all the way back to 1882 Berlin. A talented, if aimless, young German doctor, Paul Ehrlich, had just met the great microbiologist Robert Koch. Koch was giving a lecture in which he identified the pathogen responsible for tuberculosis. Ehrlich was instantly fascinated by Koch and microbiology. Unknown to himself, he had just taken the first step on a path that would help change the way disease is tackled forever1. The late 1800’s were a time of dynamic change in the sciences. Charles Darwin had proposed his Theory of Natural Selection and Thomas Edison had given us the light bulb. Amongst the many fashionable topics of the time, some biologists were fascinated by dyes; specifically the staining of living tissue. Spending all day bent over a microscope looking at the pretty colours might not seem like worthwhile science by modern standards, but these dyes had interesting properties. Dyes displayed a high level of specificity; they would only stain certain structures and pass through others. Ehrlich noticed this and soon started to think of applications for these properties. These were times when catching a chill could kill. Many well-known individuals of the time were killed in their prime due to infectious disease. Emily Brontë died from tuberculosis2, René Descartes from pneumonia3 and Pyotr Tchaikovsky died from cholera4.
    [Show full text]
  • UNIVERSITY of CALIFORNIA the Role of United States Public Health Service in the Control of Syphilis During the Early 20Th Centu
    UNIVERSITY OF CALIFORNIA Los Angeles The Role of United States Public Health Service in the Control of Syphilis during the Early 20th Century A dissertation submitted in partial satisfaction of the requirements for the degree of Doctor of Public Health by George Sarka 2013 ABSTRACT OF THE DISSERTATION The Role of United States Public Health Service in the Control of Syphilis during the Early 20th Century by George Sarka Doctor of Public Health University of California, Los Angeles, 2013 Professor Paul Torrens, Chair Statement of the Problem: To historians, the word syphilis usually evokes images of a bygone era where lapses in moral turpitude led to venereal disease and its eventual sequelae of medical and moral stigmata. It is considered by many, a disease of the past and simply another point of interest in the timeline of medical, military or public health history. However, the relationship of syphilis to the United States Public Health Service is more than just a fleeting moment in time. In fact, the control of syphilis in the United States during the early 20th century remains relatively unknown to most individuals including historians, medical professionals and public health specialists. This dissertation will explore following question: What was the role of the United States Public Health Service in the control of syphilis during the first half of the 20th century? This era was a fertile period to study the control of syphilis due to a plethora of factors including the following: epidemic proportions in the U.S. population and military with syphilis; the ii emergence of tools to define, recognize and treat syphilis; the occurrence of two world wars with a rise in the incidence and prevalence of syphilis, the economic ramifications of the disease; and the emergence of the U.S.
    [Show full text]
  • Syphilis - Its Early History and Treatment Until Penicillin, and the Debate on Its Origins
    History Syphilis - Its Early History and Treatment Until Penicillin, and the Debate on its Origins John Frith, RFD Introduction well as other factors such as education, prophylaxis, training of health personnel and adequate and rapid “If I were asked which is the most access to treatment. destructive of all diseases I should unhesitatingly reply, it is that which Up until the early 20th century it was believed that for some years has been raging with syphilis had been brought from America and the New impunity ... What contagion does World to the Old World by Christopher Columbus in thus invade the whole body, so much 1493. In 1934 a new hypothesis was put forward, resist medical art, becomes inoculated that syphilis had previously existed in the Old World so readily, and so cruelly tortures the before Columbus. I In the 1980’s palaeopathological patient ?” Desiderius Erasmus, 1520.1 studies found possible evidence that supported this hypothesis and that syphilis was an old treponeal In 1495 an epidemic of a new and terrible disease broke disease which in the late 15th century had suddenly out among the soldiers of Charles VIII of France when evolved to become different and more virulent. Some he invaded Naples in the first of the Italian Wars, and recent studies however have indicated that this is not its subsequent impact on the peoples of Europe was the case and it still may be a new epidemic venereal devastating – this was syphilis, or grande verole, the disease introduced by Columbus from America. “great pox”. Although it didn’t have the horrendous mortality of the bubonic plague, its symptoms were The first epidemic of the ‘Disease of Naples’ or the painful and repulsive – the appearance of genital ‘French disease’ in Naples 1495 sores, followed by foul abscesses and ulcers over the rest of the body and severe pains.
    [Show full text]
  • The Impact of Polypharmacology on Chemical Biology
    The impact of polypharmacology on chemical biology Albert Antolín Hernández TESI DOCTORAL UPF / ANY 2014 DIRECTOR DE LA TESI: Dr. Jordi Mestres CEXS Department The research in this Thesis has been carried out at the Systems Pharmacology Research Group, within the Research Programme on Biomedical Informatics (GRIB) at Parc de Recerca Biomèdica de Barcelona (PRBB). The research presented in this Thesis has been supported by Ministerio de Ciencia e Innovación Project BIO2005-041171, BIO2008-02329, BIO2011- 26669 and PTA2009-1865P and the Catalan Government grant 2013FIB2- 00073. Printing funded by the Fundació IMIM’s program “Convocatòria d'ajuts 2014 per a la finalització de tesis doctorals de la Fundació IMIM.” A en Juan, Per ensenyar-me que la realitat també pot ser màgica. Agraïments Una tesi és molt més que un escrit final. Son les persones, les experiències i les vivències que m’han acompanyat durant tots aquests anys. És per això que en les següents ratlles voldria agrair-vos a tots aquells que heu format part i heu fet possible aquesta aventura! En primer lloc, voldria donar les gràcies al meu director de tesi, el Dr. Jordi Mestres. Gràcies per confiar en mi, per ajudar-me amb el finançament abans que em donessin la beca i per permetre’m formar part del Laboratori i aplicar el software que durant anys heu anat desenvolupant. Ha estat una oportunitat increïble! També pels moments més difícils, per la canya i els reptes amb que he anat creixent, per tot l’esforç depositat en aquesta tesi i per les interessants converses finals sobre
    [Show full text]